A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 103)
A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Clinical Operations Team
- 電話番号:+1-800-794-5434
- メール:ClinicalTrials@coherus.com
研究場所
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- 募集
- Fred Hutchinson Cancer Center
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
- Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgment.
mCRPC:
- Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with focal small cell or neuroendocrine (NE) features based on immunohistochemistry (IHC) alone is permitted. However, small cell carcinoma, carcinoid tumor, mixed NE carcinoma, or large cell NE carcinoma is not permitted.
- Measurable Castration-resistant Prostate Cancer (mCRPC) as defined by PCWG3 criteria. Participant must have mCRPC that is metastatic either to bone, lymph node (LN), or both without clear evidence of either measurable or nonmeasurable metastasis to visceral organs at the time of screening scan.
- Participants must have been previously treated with at least 1 prior androgen-receptor pathway inhibitor (ARPI) (ie, abiraterone acetate, enzalutamide, apalutamide, darolutamide).
- Participants must have received at least one prior taxane therapy unless the participant is ineligible or refused. Participants must not have received other prior cytotoxic chemotherapy (ie, cisplatin, carboplatin, etoposide).
- Prior orchiectomy or medical castration. Participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analog with testosterone ≤50 nanogram per deciliter (ng/dL) prior to the first dose of study drug and must continue this therapy throughout the treatment phase.
Key Exclusion Criteria:
- History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years.
- Prior exposure to anti-CCR8 antibody agents.
- Prior allogeneic hematological stem cell transplantation or organ transplantation.
mCRPC:
- Any known prior history of brain metastases of prostate cancer (PCa).
- Treatment with antineoplastic therapy (including but not limited to cytotoxic chemotherapy, biologic agents, and investigational agents) other than ADT or ARPI within 28 days or <5× the elimination half-life (t½), whichever is earlier, before Day 1.
- Prior exposure to a T cell engager or human kallikrein 2 (KLK2) targeted therapy.
- Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.
Additional protocol-defined inclusion and exclusion criteria apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:mCRPC: Tagmokitug + Pasritamig
|
Specified dose on specified days. Specified dose on specified days. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of Participants with Dose-limiting Toxicities (DLTs)
時間枠:Up to 56 Days
|
Up to 56 Days
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
客観的奏効率 (ORR)
時間枠:最長約2.5年
|
最長約2.5年
|
|
応答期間 (DOR)
時間枠:最長約2.5年
|
最長約2.5年
|
|
mCRPC: Prostate Specific Antigen >=50% Response Rate (PSA50) per Prostate Cancer Working Group 3 (PCWG3) Criteria
時間枠:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Disease Control Rate (DCR)
時間枠:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
mCRPC: Radiographic Progression-free Survival (rPFS)
時間枠:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Progression-free Survival (rPFS)
時間枠:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Maximum Observed Serum Concentration of Tagmokitug (Cmax)
時間枠:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Concentration of Tagmokitug Immediately Before the Next Dose (Ctrough)
時間枠:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
|
Number of Participants with Anti-drug Antibodies to Tagmokitug
時間枠:Up to approximately 2.5 years
|
Up to approximately 2.5 years
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Study Director、Coherus Oncology
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CHS-114-103
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。